Interestingly, in human xenograft and transgenic mammary cancer models, RAS-PI3K-AKT inhibitors at a dose that did not reduce tumor growth increased tumor perfusion and reduced hypoxia (58). The gene discussed is AKT1; the disease is neoplasm.